Journal of the National Cancer Institute Advance Access originally published online on August 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(16):1129-1131; doi:10.1093/jnci/djn301
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© Oxford University Press 2008.
NEWS |
No Rest for Fatigue Researchers
| The first 150 words of the full text of this article appear below. |
Fatigue is the most important side effect of cancer and cancer treatment, according to a recent study of patients and professionals in major cancer centers across the United States. Led by David Cella, Ph.D., at Evanston Northwestern Healthcare and Northwestern University's cancer center in Chicago, the study confirms not only that cancer-related fatigue is common but also that it affects patients with diverse cancers. Patients undergoing treatment for nine different kinds of advanced cancer ranked it as their most important symptom or concern; patients with two other kinds of cancer ranked it among their top five concerns.
Unfortunately, fatigue is still harder to treat than other common, cancer-related symptoms such as pain and nausea. In this issue of the Journal (1155–1166), Ollie Minton, M.D., of St. George's University of London and colleagues report their findings from a systematic review and meta-analysis of drugs targeted at cancer-related fatigue. Limiting their review
Defining and Measuring
Current Options
Exercise and Counseling
What Is Fatigue?